Paycom Software’s Chad Richison and Advanced Micro Devices’ Lisa Su are among the top paid CEOs in the S&P 500 index.

The state health department said nearly 17,000 people had filled up four days of appointments for the speedway clinic being held Friday through Monday. (AP Photo/Darron Cummings)SACRAMENTO, Calif. -- California state prisons will soon resume limited in-person visits with inmates more than a year after they were halted because of the coronavirus pandemic. Museums, aquariums, retail businesses and shops, hair salons and personal care businesses can operate at 100% capacity indoors and outdoors. The three joined neighboring Santa Mateo County on Tuesday as the latest Bay Area counties to move into California’s “moderate” tier for coronavirus restrictions. Chicago Department of Public Health Commissioner Dr. Allison Arwady says the biggest driver behind the increase is young adults.

An increasing number of COVID-19 vaccination sites around the U.S. are canceling appointments because of vaccine shortages in a rollout so rife with confusion and unexplained bottlenecks. However, state officials did not explain how regional per capita virus cases and transmission rates that also were released might influence how much ICU space will be available in four weeks. Last week, state health officials told The Associated Press they were keeping all the data secret because it is complicated and might mislead the public. State health officials said Monday that the Brazil P.1 variant was found in a specimen from a Minnesota resident who had recently been to Brazil. Health officials are also worried about variants that were first reported in the U.K. and South Africa.

The latest vaccine developments are also helping to raise hopes that some normalcy will eventually be restored to everyday life and the economy. The S&P 500 rose 0.6% to 3,577.59 on Monday. Roughly 73% of the stocks in the S&P 500 rose. Even with its weekly decline last week, the S&P 500 is on track for a 9.4% gain this month. The string of upbeat news about vaccine development has been butting up against increased caution as the virus continues to threaten the economy.

On Wednesday, the U.S. Food and Drug Administration said it has approved the drug for treating Ebola in both adults and children. (Regeneron via AP)U.S. regulators Wednesday approved the first drug for the treatment of Ebola. The Food and Drug Administration OK'd the drug developed by Regeneron Pharmaceuticals for treating adults and children with the Zaire Ebola virus strain, the most deadly of six known types. Regeneron's treatment is a combination of three antibodies that work by killing the virus. After four weeks, about a third of those who got Regeneron's drug had died.

Three additional deaths from the pandemic also were disclosed Friday by state health officials as fatalities from the pandemic surpassed 900. ___RENO, Nev. -- A recent spike in COVID-19 cases at the University of Nevada, Reno is prompting the school to suspend all in-class instruction effective Nov. 30. County officials previously required bars to cut indoor seating occupancy by half, close dance floors and discontinue live performances and entertainment. On Monday, Yellowstone County Health Officer John Felton announced case benchmarks that would lead to county health officials to limit the allowed capacity of bars, restaurants and churches to 25%. The measures include closing gyms and theaters after Ontario registered a record 939 coronavirus cases on Friday.

DETROIT Medical experts have been using coronavirus antibodies in the form of convalescent plasma to help patients fighting COVID-19, but new research could take that concept to the next level. RELATED: Evrod Cassimy donates plasma, coronavirus antibodies to help othersThe idea is creative a drug that would not only treat those infected with coronavirus, but potentially help prevent infections too. According to biotechnology company Regeneron Pharmaceuticals, phase three clincal trials are now in the works for REGN-COV2, their combination antibody treatment for COVID-19. The drug is a combination of two antibodies -- the proteins the body makes to naturally fight infections. Regeneron was awarded a $450 million contract to manufacture and supply the antibody treatment as part of the federal governments push to get a vaccine by January 2021.